Top 5 Stem Cell Therapy Companies : Key Trends, Growth Drivers and Insights Report
RELEASE DATE: Oct 2024 Author: Spherical Insights Request Free Sample
What Is Stem Cell Therapy?
The technique of introducing stem cells from the body into sick or injured tissues, including an osteoarthritis joint or a ruptured ligament in the knee, is known as stem cell therapy. Unspecialized cells called stem cells can divide among themselves to regenerate itself. They may develop into a particular type of tissue or organ cell in specific circumstances. Stem cells act as an internal repair mechanism in many tissues, regenerating and changing into the appropriate cells to replace damaged or dead tissue.
Growth Factors and Trends in the Stem Cell Therapy Industry
1. The increase in long-term health incidence and prevalence will fuel market expansion
Most people worldwide are afflicted with chronic illnesses. Globally, one in three adults suffers from a chronic condition. Numerous people's health and quality of life have been negatively influenced by chronic diseases. Chronic diseases can lead to hospital stays, long-term disability, a reduction in quality of life, and even death. Examples of these diseases include cancer, orthopedic and neurological disorders, severe injuries, cardiac and digestive problems, and chronic injuries.
2. Cell Transplantation
Stem cell treatments use the regenerative power of stem cells to substitute or restore injured organs and tissues. This method tackles issues with the treatment of chronic illnesses, such as rejection of transplants and the scarcity of donor organs. CRISPR and generated pluripotent stem cells (iPSCs) are two recent developments in stem cell therapy. By facilitating the production of patient-specific cells and lowering the possibility of immunological rejection, they greatly improve the safety and effectiveness of cell transplantation. Furthermore, precision tissue engineering is advanced and the potential of regenerative medicine is expanded through the combination of 3D bioprinting and stem cell technologies.
3. Increasing Recognition and Requests for Customized Healthcare
One of the main factors propelling the stem cell therapy market is the rising need for regenerative and customized medicine, as well as the public's and healthcare professionals' increased knowledge of and acceptance of stem cell therapies. The industry is expanding because patients are looking for more individualized and efficient treatments, and stem cell therapies promise to provide just that.
4. Cell Seeding
Cell seeding facilitates efficient tissue regeneration by optimizing the integration and dispersion of cells within scaffolds. By using methods like electrospinning and microfluidic devices to increase scaffold colonization and boost cell placement accuracy, this approach enables homogeneous cell growth and differentiation. Cell seeding facilitates the uniform dispersion of chondrocytes on biodegradable scaffolds to support steady tissue growth and healing in cartilage repair. Furthermore, the co-culturing of several cell types to replicate the native cellular milieu is made possible by cell seeding technology, which makes complex tissue structures possible.
Key Market Insights:
The global stem cell therapy market size was valued at USD 12.40 billion in 2023 and is projected to USD 44.20 billion by 2033, exhibiting a CAGR of 13.55% during the forecast period 2023-2033. Several companies leading the global stem cell therapy market are AstraZeneca, Amgen, Celgene Corporation, ReNeuron Group plc, Biovault Family, Precious Cells International Ltd, Mesoblast Ltd, Opexa Therapeutics Inc., JCR Pharmaceuticals Co., Ltd., and Takeda Pharmaceutical Company Limited.
List of Key Companies in the Stem Cell Therapy Industry
- AstraZeneca
- Amgen
- Celgene Corporation
- ReNeuron Group plc
- Biovault Family
- Precious Cells International Ltd
- Mesoblast Ltd
- Opexa Therapeutics Inc.
- JCR Pharmaceuticals Co., Ltd.
- Takeda Pharmaceutical Company Limited
Top 5 Players in the Stem Cell Therapy Industry
1. AstraZeneca Plc
Headquarters: Cambridge, United Kingdom
AstraZeneca Plc is a multinational corporation that focuses on pharmaceutical development, research, and manufacturing. Its portfolio includes therapies for cancer treatment, heart, kidney, metabolic, and respiratory illnesses. AstraZeneca was established in 1999 through the combination of Astra of Sweden and Zeneca Group of the United Kingdom. The company distributes name-brand medications in a number of important therapeutic areas, such as immunology, cancer, diabetes, cardiovascular, respiratory, gastrointestinal, and uncommon disorders. Nearly one-third of sales originate from the United States, while overseas markets account for the remainder of sales.
2. Amgen Inc
Headquarters: California, United States
The American global biopharmaceutical business Amgen Inc., formerly known as Applied Molecular Genetics Inc., is based in Thousand Oaks, California. Amgen, one of the biggest independent biotechnology businesses in the world as of 2022, employs about 24,000 people overall. The first name of the business, Applied Molecular Genetics, which was adopted as the official name in 1983, is portmanteaued to become "AMGen." Amgen concentrates on areas with a high level of unmet medical need and uses its knowledge of these areas to work toward finding solutions that would enhance people's lives and improve health outcomes. Since its founding as a biotechnology pioneer in 1980, Amgen has expanded to become one of the top independent biotechnology businesses in the world, serving millions of patients globally and now working on a pipeline of innovative drugs.
3. Celgene Corporation
Headquarters: New Jersey, United States
Pharmaceutical manufacturer Celgene Corporation produces medications for immunology and cancer. Its main offering is Revlimid (lenalidomide), a medication used to treat anemias and multiple myeloma. Celgene belonged to Celanese. After merging with American Hoechst, Celanese finalized the corporate spin-off of Celgene in 1986. Bristol Myers Squibb owns Celgene. The main offering of the biopharmaceutical company is Revlimid, a multiple myeloma medication that is authorized in the US, Europe, and a few other chosen regions. Another MDS medicine known as Vidaza is the company's second-biggest sale; in Europe, the medication is also approved to treat leukemia. The primary focus of Celgene Corporation, a diversified biopharmaceutical business, is the study, development, and sale of treatments intended to treat immune-inflammatory disorders and cancer.
4. ReNeuron Group PLC
Headquarters: Bridgend, UK
ReNeuron Group PLC works in the biotechnology industry. Research and clinical development of cell-based therapies are among its main pursuits. The CTX neural cell line and the human retinal progenitor cell line (hRPC) are part of the company's product pipeline. It gets money from the US and the UK. The company's primary areas of interest are cancer, inherited retinal illnesses, and stroke impairment treatment. Creation of therapies based on stem cells to treat critical limb ischemia and stroke impairment. ReN001, a therapeutic treatment for stroke patients with disabilities, is part of the company's pipeline. The organization also sells CTX cells for Parkinson's disease and stroke caused by ischemia, as well as human retinal progenitor stem cells for retinitis pigmentosa.
5. Mesoblast
Headquarters: Melbourne, Australia
Australian-based Mesoblast Limited is a provider of regenerative medicine. It aims to treat back pain, cardiovascular disease, and inflammatory illnesses. Using its unique platform for mesenchymal lineage cell technologies, Mesoblast is creating and distributing cutting-edge allogeneic cellular medications to treat complicated inflammatory illnesses that are unresponsive to traditional medical treatment. Healthy adult donors' bone marrow is used to harvest mesenchymal lineage cells, which are then expanded into a homogeneous, thoroughly defined, and incredibly repeatable cell population using patented techniques. This makes it possible to manufacture goods commercially at an industrial scale. The ability of Mesoblast cells to be given to patients without recipient immune suppression or donor-receiver matching is another important characteristic.
Recent Development
1. In January 2024, Propagenix Inc., a biotechnology firm situated in Maryland that specializes in creating technologies to support innovative methods in regenerative healthcare, has been acquired by STEMCELL Technologies, the biggest biotechnology company in Canada.
2. In September 2024, ReNeuron Group has completed a significant step in verifying its unique stem cell-derived exosome platform by generating in vivo data for CustomEX.
3. In November 2023, AstraZeneca has announced an association and partnership agreement with Cellectis, a clinical-stage biopharmaceutical business, to speed the advancement of next-generation therapies in fields with high unmet need, such as oncology, immunology, and rare illnesses.
4. In October 2023, Amgen said that it has successfully acquired Horizon Therapeutics plc for payment for $116.50 each share, for a total transaction capital value of about $27.8 billion.
5. In October 2022, a joint venture between Sysmex Corporation and JCR Pharmaceuticals Co., Ltd. was announced to conduct clinical trials, produce, and distribute items based on cell-based regenerative therapies, such as hematopoietic stem cells and other stem cells.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us